 "Strides Arcolab surges on plans to buy Aspen's generic pharma business")
Shares of Strides Arcolab have moved higher by 7% to Rs 1,171 on the BSE after the pharmaceutical company said it has inked an agreement to acquire a generic pharmaceutical business in Australia and related assets from Aspen for approximately A$380 million (Rs 1,900 crore).
“The acquisition of the business will include access to the product pipeline that was under development by Aspen and includes number of major product launches in the next six months,” Strides Arcolab said in a press release.
The company said the transactions will be financed by a combination of internal accruals and debt financing, and expects it to be immediately accretive to its earnings per share. It expects the deal to close by the end of the second quarter.
The stock opened at Rs 1,099 and touched a low of Rs 1,070 on the BSE. A combined 1.42 million shares changed hands on the counter so far on the BSE and NSE.
At 1330 hours, the stock was up 6% at Rs 1,159 on the BSE.
“The acquisition of the business will include access to the product pipeline that was under development by Aspen and includes number of major product launches in the next six months,” Strides Arcolab said in a press release.
The company said the transactions will be financed by a combination of internal accruals and debt financing, and expects it to be immediately accretive to its earnings per share. It expects the deal to close by the end of the second quarter.
The stock opened at Rs 1,099 and touched a low of Rs 1,070 on the BSE. A combined 1.42 million shares changed hands on the counter so far on the BSE and NSE.
At 1330 hours, the stock was up 6% at Rs 1,159 on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%